Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | Finanzwire

Basculer en Français

9475	Companies
185442	Keywords
117783	Articles
99298	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 03/18/2025 at 12:05, 8 months 17 days ago

Protagonist Therapeutics Recognized for Innovation in Biotech

Drug Development Healthcare Innovation Protagonist Therapeutics Peptide Therapeutics Innovative Biotech
PRESS RELEASE

published on 03/18/2025 at 12:00, 8 months 18 days ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Protagonist Therapeutics named one of Fast Company's Most Innovative Companies 2025 for pioneering peptide-based therapeutics. Recognized for groundbreaking work in drug development

Innovation Drug Development Fast Company Protagonist Therapeutics Peptide-based Therapeutics
BRIEF

published on 03/10/2025 at 13:20, 8 months 25 days ago

Protagonist Therapeutics Reports Promising Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2b Study Icotrokinra Clinical Response IL-23 Receptor
PRESS RELEASE

published on 03/10/2025 at 13:15, 8 months 25 days ago

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Protagonist Therapeutics, Inc. announces positive topline results from ANTHEM-UC Phase 2b study of icotrokinra in ulcerative colitis, meeting primary endpoint. Results indicate high clinical response and remission rates

Ulcerative Colitis Clinical Trial Protagonist Therapeutics Icotrokinra ANTHEM-UC
BRIEF

published on 03/08/2025 at 15:20, 8 months 27 days ago

Protagonist Therapeutics Unveils Promising Results for Icotrokinra in Psoriasis Treatment

Clinical Trials Protagonist Therapeutics Plaque Psoriasis Icotrokinra Treatment Efficacy
PRESS RELEASE

published on 03/08/2025 at 15:15, 8 months 27 days ago

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Protagonist Therapeutics announces new data on icotrokinra in Phase 3 studies for moderate-to-severe plaque psoriasis. Launching first head-to-head study vs. ustekinumab

Phase 3 Protagonist Therapeutics Plaque Psoriasis Icotrokinra Head-to-head Study
BRIEF

published on 02/21/2025 at 13:05, 9 months 11 days ago

Protagonist Therapeutics Announces 2024 Financial Results and Corporate Progress

Protagonist Therapeutics Financial Results 2024 Icotrokinra Milestone Rusfertide VERIFY Trial Takeda Collaboration
PRESS RELEASE

published on 02/21/2025 at 13:00, 9 months 11 days ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports $165.0 million milestone achieved in Q4 2024 and key milestones for 2025 including icotrokinra and rusfertide trial results. Financial results for Q4 2024 revealed

Financial Results Clinical Trial Milestone Protagonist Therapeutics Rusfertide
BRIEF

published on 01/30/2025 at 00:20, 10 months 6 days ago

Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Clinical Trials Investor Event Protagonist Therapeutics Rusfertide Polycythemia Vera
PRESS RELEASE

published on 01/30/2025 at 00:15, 10 months 6 days ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Protagonist Therapeutics to host investor event discussing Rusfertide Phase 3 VERIFY study design and Phase 2 data with key opinion leaders. Company also to provide commercial opportunity snapshot. Live Q&A session and lunch included

Investor Event Protagonist Therapeutics Rusfertide Phase 3 VERIFY Study Commercial Opportunity

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 27 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 32 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 11 hours 2 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 57 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 2 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 47 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 1 hour 32 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 47 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 21 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 32 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany

Les Echos

Published on 12/05/2025 at 08:45, 3 hours 17 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 18 hours 2 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 18 hours 17 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 18 hours 18 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 5 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE